Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | WRN | Q14191 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13209013 | 0.79 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HPGDPOLB | |
| SCHEMBL17028596 | 0.73 | CES2 (0.37) | SLC6A2SLC6A4SLC6A3HPGDPOLB | |
| SCHEMBL13209008 | 0.70 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15898586 | 0.68 | ALDH1A1 (0.40) | HPGDPOLBKDM4EALDH1A1MAPT | |
| SCHEMBL29268033 | 0.68 | SLC6A2 (0.30) | SLC6A2SLC6A4SLC6A3HPGDPOLB | |
| SCHEMBL2876560 | 0.68 | HPGD (0.37) | SLC6A2SLC6A4SLC6A3HPGDPOLB | |
| SCHEMBL21610764 | 0.67 | HCAR3 (0.36) | HPGDDAOALDH1A1MAPT | |
| SCHEMBL22195209 | 0.67 | HCAR3 (0.36) | HPGDDAOALDH1A1MAPT | |
| SCHEMBL9085983 | 0.66 | HTT (0.36) | SLC6A2SLC6A4SLC6A3HPGDPOLB | |
| SCHEMBL13209010 | 0.65 | HCAR3 (0.37) | SLC6A2SLC6A4HPGDWRNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107901-B1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | PIRAMAL ENTPR LTD (IN) | 2020-04-01 | — | — | EP | disclosed |
| EP-3191463-B1 | FUSED HETEROCYCLIC COMPOUNDS AS GPR120 AGONISTS | PIRAMAL ENTPR LTD (IN) | 2019-10-30 | — | — | EP | disclosed |
| US-10227360-B2 | Compounds for use as GPR120 agonists | Piramal Enterprises Limited (IN) | 2019-03-12 | — | — | US | disclosed |
| US-20170283410-A1 | FUSED HETEROCYCLIC COMPOUNDS AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2017-10-05 | — | — | US | disclosed |
| EP-3191463-A1 | FUSED HETEROCYCLIC COMPOUNDS AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2017-07-19 | — | — | EP | disclosed |
| EP-3107901-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-28 | — | — | EP | disclosed |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-01 | — | — | US | disclosed |
| WO-2016038540-A1 | FUSED HETEROCYCLIC COMPOUNDS AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-03-17 | — | — | WO | disclosed |
| WO-2015125085-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227360-B2 | Compounds for use as GPR120 agonists | GPR119, GPR55, GPR180 | SLC6A2 149/4885SLC6A4 460/4885SLC6A3 667/4885 |
| US-20170283410-A1 | FUSED HETEROCYCLIC COMPOUNDS AS GPR120 AGONISTS | GPR180, GPR55, GPR68 | SLC6A2 389/4885SLC6A4 483/4885SLC6A3 787/4885 |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | GPR119, GPR55, GPR180 | SLC6A2 149/4885SLC6A4 460/4885SLC6A3 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.